Ledraxen

Enoxaparin sodium, the active ingredient in Ledraxen, is a low molecular weight heparin presented as a sterile injectable solution for subcutaneous, intravenous, and haemodialysis use. It is employed to prevent and treat deep vein thrombosis, pulmonary embolism, and to provide anticoagulation during haemodialysis procedures.

GNH USA supplies Ledraxen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Ledraxen, a low molecular weight heparin, is indicated for several thromboembolic conditions.

- Deep vein thrombosis (DVT) prophylaxis: prevents clot formation in surgical patients at risk of DVT. - Acute deep vein thrombosis treatment: facilitates clot resolution and reduces propagation. - Pulmonary embolism prevention and treatment: lowers risk of embolic events in high‑risk patients. - Anticoagulation during haemodialysis: maintains circuit patency by inhibiting clotting.

Enoxaparin may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: erythema, pain, or bruising at the administration site. - Minor bleeding: nosebleeds, gum bleeding, or easy bruising. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Major hemorrhage: internal bleeding requiring medical intervention. - Thrombocytopenia: significant drop in platelet count, potentially leading to bleeding. - Allergic reactions: rash, urticaria, or anaphylaxis. - Elevated liver enzymes: abnormal hepatic function tests.

When using Ledraxen, certain precautions should be observed to minimize risks. - Renal impairment: adjust dose or monitor anti‑Xa levels in patients with reduced kidney function. - Concomitant anticoagulants: avoid or closely monitor when used with other anticoagulant or antiplatelet agents. - Recent surgery or trauma: assess bleeding risk before initiating therapy. - Pregnancy and lactation: use only if the potential benefit outweighs the risk, as safety data are limited. - Spinal/epidural procedures: discontinue before neuraxial anesthesia to reduce spinal hematoma risk. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Enoxaparin can interact with several medications, affecting its anticoagulant effect.

Major Interactions (Avoid): - Warfarin: combined use markedly increases bleeding risk. - Direct oral anticoagulants (e.g., rivaroxaban, apixaban): additive anticoagulation may cause severe hemorrhage. - Thrombolytic agents (e.g., alteplase): heightened risk of major bleeding.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase minor bleeding. - Antiplatelet drugs (e.g., aspirin, clopidogrel): monitor for enhanced bleeding. - Heparin products: overlapping anticoagulant effect requires careful monitoring.